FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
+40.37%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$224M
AUM Growth
+$224M
(+36%)
Cap. Flow
+$2.72M
Cap. Flow
% of AUM
1.21%
Top 10 Holdings %
Top 10 Hldgs %
84.52%
Holding
14
New
–
Increased
5
Reduced
5
Closed
–
Top Buys
| 1 |
AMRN
Amarin Corp
AMRN
|
$3.68M |
| 2 |
Iovance Biotherapeutics
IOVA
|
$3.09M |
| 3 |
Amicus Therapeutics
FOLD
|
$2.49M |
| 4 |
Axsome Therapeutics
AXSM
|
$2.18M |
| 5 |
Karyopharm Therapeutics
KPTI
|
$1.7M |
Top Sells
| 1 |
argenx
ARGX
|
$5.9M |
| 2 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$2.71M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$872K |
| 4 |
Neurogene
NGNE
|
$664K |
| 5 |
Insmed
INSM
|
$275K |
Sector Composition
| 1 | Healthcare | 94.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Acadia Pharmaceuticals
ACAD
$4.38B
| $28.4M | 12.66% | 585,517 -18,000 | -3% | -$872K |
|
|
2
Insmed
INSM
$28.8B
| $27.8M | 12.42% | 1,010,797 -10,000 | -1% | -$275K |
|
|
ZGNX
3
DELISTED
Zogenix, Inc.
ZGNX
| $26.3M | 11.71% | 971,875 | – | – |
|
|
4
Amicus Therapeutics
FOLD
$2.34B
| $22.7M | 10.13% | 1,505,395 +165,000 | +12% | +$2.49M |
|
|
5
Axsome Therapeutics
AXSM
$6.05B
| $17.8M | 7.93% | 216,098 +26,500 | +14% | +$2.18M |
|
|
6
Iovance Biotherapeutics
IOVA
$807M
| $16.6M | 7.39% | 603,890 +112,500 | +23% | +$3.09M |
|
|
ALLK
7
DELISTED
Allakos
ALLK
| $12.8M | 5.73% | 178,662 | – | – |
|
|
8
Neurogene
NGNE
$264M
| $12.8M | 5.7% | 770,073 -40,000 | -5% | -$664K |
|
|
9
Karyopharm Therapeutics
KPTI
$61.7M
| $12.4M | 5.51% | 652,351 +90,000 | +16% | +$1.7M |
|
|
TRIL
10
DELISTED
Trillium Therapeutics Inc.
TRIL
| $12M | 5.35% | 1,483,181 -335,000 | -18% | -$2.71M |
|
|
11
argenx
ARGX
$43.6B
| $11.4M | 5.07% | 50,450 -26,188 | -34% | -$5.9M |
|
|
AMRN
12
Amarin Corp
AMRN
$311M
| $9.71M | 4.33% | 1,403,237 +531,523 | +61% | +$3.68M |
|
13
Enanta Pharmaceuticals
ENTA
$180M
| $8.53M | 3.81% | 169,949 | – | – |
|
14
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $5.1M | 2.27% | 200,125 | – | – |
|